OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer – Nasdaq
|
OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
Nasdaq ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The study … |
GeekWire |
Fred Hutch licenses new immunotherapy treatment to Mustang Bio, preps clinical trials in Seattle
GeekWire The technology is the basis for a new kind of CAR T immunotherapy treatment, which genetically engineers a patient’s immune cells to fight cancer. Similar treatments have been under development at biotech companies across the country for several years, … Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed ImmunotherapiesPharmiWeb.com (press release) |
GeekWire |
Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies
GlobeNewswire (press release) 14, 2017 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) … Fred Hutch licenses new immunotherapy treatment to Mustang Bio, preps pre-clinical trials in SeattleGeekWire |
|
$475000 for a Cancer Drug? Time to Put a Lid on Costs
Undark Magazine But much of the research that led to biologic drugs and treatments like CAR–T was funded by taxpayers. Novartis didn’t invent this half-million-dollar drug, and it’s questionable whether the Penn scientists from whom it bought a license invented it … OPINION: Don’t put profits over curing cancerKansas State Collegian |
|
$475000 for a Cancer Drug? Time to Put a Lid on Costs
Undark Magazine But much of the research that led to biologic drugs and treatments like CAR–T was funded by taxpayers. Novartis didn’t invent this half-million-dollar drug, and it’s questionable whether the Penn scientists from whom it bought a license invented it … OPINION: Don’t put profits over curing cancerKansas State Collegian |